OBI Pharma Signs Collaboration and License Agreement with Novartis
2026.Oct.07
Award & Certification
Following Presidential Office Recognition, OBI Pharma Showcases the Strength of Its Obrion® ADC Platform and Accelerates Global Licensing to Capture Expanding Market Opportunities
2026.Jul.06
Award & Certification
OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards
2026.Jun.26
Corporate
OBI Holds 2026 Annual Shareholders’ Meeting
Capturing Global Opportunities in Next-Generation ADCs with Its Proprietary Obrion® Platform to Advance Bispecific Dual-Payload ADCs and International Licensing Strategy
2026.Jun.11
Corporate
OBI Presents Three Featured Talks at the 2026 World ADC Summit South Korea
Highlighting GlycOBI® and Dual-Payload ADC Technologies
2026.Apr.24
Corporate
OBI Announces US FDA Registration and Activation of HYProtecan™ Type II Drug Master File
Supporting Obrion Engine™ ADC Technologies and Enhancing Regulatory Efficiency
2026.Apr.16
Media
OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance
2026.Apr.15
Corporate
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.
2026.Apr.09
Corporate
OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai
Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design
2026.Apr.02
Corporate
OBI Participated in BIO-Europe Spring®, Advancing International Business Development
Engaged with Multiple Global Pharma Companies for Licensing Discussions